We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » In Enforcement Crackdown, FDA Withdraws 216 Generic Drug Applications
In Enforcement Crackdown, FDA Withdraws 216 Generic Drug Applications
Effective Nov. 21, the FDA is pulling the approvals of 216 abbreviated new drug applications (ANDAs) as it cracks down on drug sponsors who have failed to submit the required annual reports.